BR0113574A - Derivados de pirazol e uso dos mesmos como inibidores de proteìna quinase - Google Patents
Derivados de pirazol e uso dos mesmos como inibidores de proteìna quinaseInfo
- Publication number
- BR0113574A BR0113574A BR0113574-0A BR0113574A BR0113574A BR 0113574 A BR0113574 A BR 0113574A BR 0113574 A BR0113574 A BR 0113574A BR 0113574 A BR0113574 A BR 0113574A
- Authority
- BR
- Brazil
- Prior art keywords
- formula
- compounds
- syndrome
- protein kinase
- kinase inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Biomedical Technology (AREA)
- Gynecology & Obstetrics (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Pregnancy & Childbirth (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
"DERIVADOS DE PIRAZOL E USO DOS MESMOS COMO INIBIDORES DE PROTEìNA QUINASE". A invenção proporciona compostos de fórmula 1 em que R^ 1^, R^ 2^, R^ 3^, e R^ 4^ sejam tal como se definem, e os seus sais farmaceuticamente aceitáveis. Anunciam-se os compostos de fórmula 1 como tendo atividade inibidora de cdk2 e GSK-3. Composições farmacêuticas e métodos que incluam compostos de fórmula (1) para o tratamento e a prevenção de doenças e estados incluindo o crescimento anormal das células, tais como o câncer, e doenças e estados neurodegenerativos e os que sejam afetados pela neurotransmissão de dopamina. Também se descrevem composições farmacêuticas e métodos que incluam compostos de fórmula 1 para o tratamento das fertilidade masculina e mobilidade do esperma; diabetes mellitus; déficet de tolerância à glicose; síndrome metabólico ou síndrome X; síndrome policístico dos ovários; adipogênese e obesidade; miogênese e fragilidade, por exemplo o declínio no desempenho físico relacionado com a idade; sarcopenia aguda, por exemplo a atrofia muscular e/ou a caquéxia associada a queimaduras, permanência em acamado, imobilização dos membros, ou grande cirurgia toráxica, abdominal, e/ou a cirurgia ortopédica; sépsia; perda capilar, enfraquecimento do cabelo, e calvície; e imunodeficiência.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22941500P | 2000-08-31 | 2000-08-31 | |
PCT/IB2001/001540 WO2002018346A1 (en) | 2000-08-31 | 2001-08-24 | Pyrazole derivatives and their use as protein kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0113574A true BR0113574A (pt) | 2003-07-22 |
Family
ID=22861151
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0113574-0A BR0113574A (pt) | 2000-08-31 | 2001-08-24 | Derivados de pirazol e uso dos mesmos como inibidores de proteìna quinase |
Country Status (38)
Country | Link |
---|---|
EP (1) | EP1313710A1 (pt) |
JP (1) | JP2004507526A (pt) |
KR (1) | KR20030027093A (pt) |
CN (1) | CN1518543A (pt) |
AP (1) | AP2001002266A0 (pt) |
AR (1) | AR035345A1 (pt) |
AU (1) | AU2001280009A1 (pt) |
BG (1) | BG107455A (pt) |
BR (1) | BR0113574A (pt) |
CA (1) | CA2420363A1 (pt) |
CR (1) | CR6881A (pt) |
CZ (1) | CZ2003468A3 (pt) |
DO (1) | DOP2001000243A (pt) |
DZ (1) | DZ3398A1 (pt) |
EA (1) | EA200300205A1 (pt) |
EC (1) | ECSP034480A (pt) |
EE (1) | EE200300085A (pt) |
GT (1) | GT200100179A (pt) |
HN (1) | HN2001000192A (pt) |
HR (1) | HRP20030140A2 (pt) |
HU (1) | HUP0302669A3 (pt) |
IL (1) | IL154016A0 (pt) |
IS (1) | IS6687A (pt) |
MA (1) | MA26946A1 (pt) |
MX (1) | MXPA03001785A (pt) |
NO (1) | NO20030958L (pt) |
NZ (1) | NZ523656A (pt) |
OA (1) | OA12368A (pt) |
PA (1) | PA8528101A1 (pt) |
PE (1) | PE20020470A1 (pt) |
PL (1) | PL360742A1 (pt) |
SK (1) | SK2002003A3 (pt) |
SV (1) | SV2002000618A (pt) |
TN (1) | TNSN01132A1 (pt) |
UY (1) | UY26909A1 (pt) |
WO (1) | WO2002018346A1 (pt) |
YU (1) | YU14703A (pt) |
ZA (1) | ZA200301064B (pt) |
Families Citing this family (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1158985B1 (en) | 1999-01-13 | 2011-12-28 | Bayer HealthCare LLC | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
US6660731B2 (en) | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6610677B2 (en) | 2000-09-15 | 2003-08-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
DE60120193T2 (de) | 2000-09-15 | 2007-03-29 | Vertex Pharmaceuticals Inc., Cambridge | Pyrazolverbindungen als protein-kinasehemmer |
US6613776B2 (en) | 2000-09-15 | 2003-09-02 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
ATE528303T1 (de) | 2000-12-21 | 2011-10-15 | Vertex Pharma | Pyrazoleverbindungen als proteinkinasehemmer |
ATE372114T1 (de) * | 2001-09-27 | 2007-09-15 | Applied Research Systems | Verfahren zur erhöhung des testosteronspiegels |
AU2003209119A1 (en) | 2002-02-11 | 2003-09-04 | Bayer Pharmaceuticals Corporation | Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors |
SI1478358T1 (sl) | 2002-02-11 | 2013-09-30 | Bayer Healthcare Llc | Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi |
AU2003254337A1 (en) * | 2002-07-17 | 2004-02-02 | Pharmacia Italia S.P.A. | Heterobicyclic pyrazole derivatives as kinase inhibitors |
CA2501799C (en) | 2002-10-09 | 2008-06-17 | Pfizer Products Inc. | Pyrazole compounds for treatment of neurodegenerative disorders |
US7582630B2 (en) * | 2002-10-15 | 2009-09-01 | Smithkline Beecham Corporation | Pyradazine compounds as GSK-3 inhibitors |
US7507834B2 (en) | 2003-02-27 | 2009-03-24 | Smithkline Beechan Corporation | Substituted anilinopyrazoles |
DK1636585T3 (da) | 2003-05-20 | 2008-05-26 | Bayer Pharmaceuticals Corp | Diarylurinstoffer med kinasehæmmende aktivitet |
JP4220548B2 (ja) * | 2003-06-05 | 2009-02-04 | エラン ファーマシューティカルズ,インコーポレイテッド | アシル化されたアミノ酸・アミジルピラゾール、および関連化合物 |
EP1651612B9 (en) | 2003-07-22 | 2012-09-05 | Astex Therapeutics Limited | 3,4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators |
CL2004001834A1 (es) | 2003-07-23 | 2005-06-03 | Bayer Pharmaceuticals Corp | Compuesto 4-{4-[3-(4-cloro-3-trifluorometilfenil)-ureido]-3-fluorofenoxi}-piridin-2-metilamida, inhibidor de la raf, vegfr, p38 y pdgfr quinasas, sus sales; composiicon farmaceutica; combinacion farmaceutica; y su uso para tratar trastornos hiperprol |
BRPI0412820A (pt) * | 2003-07-25 | 2006-09-26 | Pfizer | compostos de aminopirazol e utilização como inibidores de chk1 |
US7671072B2 (en) * | 2003-11-26 | 2010-03-02 | Pfizer Inc. | Aminopyrazole derivatives as GSK-3 inhibitors |
US7244757B2 (en) * | 2004-04-01 | 2007-07-17 | Pfizer Inc | Pyrazole-amine compounds for the treatment of neurodegenerative disorders |
WO2005103010A2 (en) * | 2004-04-21 | 2005-11-03 | Astrazeneca Ab | Pyrazole derivatives useful for the treatment of cancer |
CN101010315A (zh) | 2004-04-30 | 2007-08-01 | 拜耳制药公司 | 用于治疗癌症的取代的吡唑基脲衍生物 |
US7498342B2 (en) | 2004-06-17 | 2009-03-03 | Plexxikon, Inc. | Compounds modulating c-kit activity |
WO2006004865A1 (en) * | 2004-06-29 | 2006-01-12 | Rigel Pharmaceuticals, Inc. | 2-substituted quinoline compounds and their uses as inhibitors of the ige receptor signaling cascade |
US7491720B2 (en) | 2004-10-29 | 2009-02-17 | Banyu Pharmaceutical Co., Ltd. | Aminopyridine derivatives having Aurora A selective inhibitory action |
US8153630B2 (en) | 2004-11-17 | 2012-04-10 | Miikana Therapeutics, Inc. | Kinase inhibitors |
US8404718B2 (en) | 2005-01-21 | 2013-03-26 | Astex Therapeutics Limited | Combinations of pyrazole kinase inhibitors |
AR054425A1 (es) | 2005-01-21 | 2007-06-27 | Astex Therapeutics Ltd | Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico. |
PT1846394E (pt) | 2005-02-04 | 2012-01-05 | Astrazeneca Ab | Derivados de pirazolilaminopiridina úteis como inibidores da quinase |
EP1847531A4 (en) * | 2005-02-09 | 2009-04-22 | Takeda Pharmaceutical | PYRAZOLE DERIVATIVE |
EP1853588B1 (en) | 2005-02-16 | 2008-06-18 | AstraZeneca AB | Chemical compounds |
MX2007014328A (es) | 2005-05-16 | 2008-02-12 | Astrazeneca Ab | Compuestos quimicos. |
EP1741708A1 (en) * | 2005-06-28 | 2007-01-10 | Sanofi-Aventis Deutschland GmbH | Heteroaryl-substituted amides comprising an unsaturated or cyclic linker group, and their use as pharmaceuticals |
CA2620333A1 (en) | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
EP2258358A3 (en) | 2005-08-26 | 2011-09-07 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
KR20140025610A (ko) | 2005-09-30 | 2014-03-04 | 미카나 테라퓨틱스, 인크. | 치환된 피라졸 화합물 |
EP1940389A2 (en) | 2005-10-21 | 2008-07-09 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
KR20080063846A (ko) | 2005-10-28 | 2008-07-07 | 아스트라제네카 아베 | 암 치료에서 티로신 키나제 억제제로 사용하기 위한4-(3-아미노피라졸)피리미딘 유도체 |
CA2625210A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
CA2627830A1 (en) | 2005-11-03 | 2007-05-18 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
US7572809B2 (en) * | 2005-12-19 | 2009-08-11 | Hoffmann-La Roche Inc. | Isoquinoline aminopyrazole derivatives |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
AU2007249399A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
PL2086642T3 (pl) * | 2006-10-18 | 2015-02-27 | Periness Ltd | DNaza do leczenia męskiej subpłodności |
JP5406030B2 (ja) | 2006-10-21 | 2014-02-05 | アボット ゲーエムベーハー ウント カンパニー カーゲー | 複素環化合物およびそれらのグリコーゲンシンターゼキナーゼ3阻害薬としての使用 |
WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
US7737149B2 (en) * | 2006-12-21 | 2010-06-15 | Astrazeneca Ab | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof |
CN101641099A (zh) | 2007-01-24 | 2010-02-03 | 葛兰素集团有限公司 | 包含3,5-二氨基-6-(2,3-二氯苯基)-1,2,4-三嗪或r(-)-2,4-二氨基-5-(2,3-二氯苯基)-6-氟甲基嘧啶和nk1的药物组合物 |
WO2009012283A1 (en) | 2007-07-17 | 2009-01-22 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
WO2009017453A1 (en) * | 2007-07-30 | 2009-02-05 | Astrazeneca Ab | New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958 |
US8212045B2 (en) | 2007-09-21 | 2012-07-03 | Array Biopharma, Inc. | Pyridin-2-yl-amino-1, 2, 4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus |
WO2009130900A1 (ja) * | 2008-04-24 | 2009-10-29 | 日本曹達株式会社 | オキシム誘導体、中間体化合物および植物病害防除剤 |
US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
ES2552386T3 (es) | 2009-04-03 | 2015-11-27 | F. Hoffmann-La Roche Ag | Composiciones de {3-[5-(4-cloro-fenil)-1H-pirrol[2,3-b]piridin-3-carbonil]-2,4-difluoro-fenil}-amida del ácido propano-1-sulfónico y usos de las mismas |
JP2013506691A (ja) * | 2009-10-02 | 2013-02-28 | バーテックス ファーマシューティカルズ インコーポレイテッド | ホスファチジルイノシトール3−キナーゼのピラゾール阻害薬 |
JP2013510166A (ja) | 2009-11-06 | 2013-03-21 | プレキシコン インコーポレーテッド | キナーゼ調節のための化合物、方法およびその適用 |
EP2621914B1 (en) | 2010-09-27 | 2016-12-28 | Abbott GmbH & Co. KG | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
US9090592B2 (en) | 2010-12-30 | 2015-07-28 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
AU2012214762B2 (en) | 2011-02-07 | 2015-08-13 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
TWI558702B (zh) | 2011-02-21 | 2016-11-21 | 普雷辛肯公司 | 醫藥活性物質的固態形式 |
US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
ES2671398T3 (es) | 2013-08-16 | 2018-06-06 | Merck Patent Gmbh | Derivados de ciclopentilamina 3-sustituida |
CN106580986B (zh) * | 2016-11-28 | 2017-09-15 | 王保亮 | 一种治疗少弱精子症的药物组合物 |
TW202043205A (zh) | 2018-12-31 | 2020-12-01 | 美商拜歐米富士恩有限公司 | Menin-mll相互作用之抑制劑 |
SG11202106304RA (en) | 2018-12-31 | 2021-07-29 | Biomea Fusion Llc | Irreversible inhibitors of menin-mll interaction |
CN113330000A (zh) * | 2019-01-31 | 2021-08-31 | 辉瑞公司 | 具有对cdk2的抑制活性的3-羰基氨基-5-环戊基-1fi-吡咯化合物 |
TW202229268A (zh) * | 2020-12-22 | 2022-08-01 | 大陸商上海拓界生物醫藥科技有限公司 | Cdk2抑制劑及其製備方法 |
AR126251A1 (es) | 2021-06-28 | 2023-10-04 | Blueprint Medicines Corp | Inhibidores de cdk2 |
TW202317564A (zh) * | 2021-07-01 | 2023-05-01 | 大陸商上海拓界生物醫藥科技有限公司 | Cdk2抑制劑及其製備方法和用途 |
TW202325280A (zh) * | 2021-11-09 | 2023-07-01 | 大陸商上海拓界生物醫藥科技有限公司 | 一種胺基吡唑衍生物及其製備方法和用途 |
WO2023092088A1 (en) * | 2021-11-19 | 2023-05-25 | Blueprint Medicines Corporation | Cdk2 inhibitors and methods of making and using same |
WO2023239629A1 (en) * | 2022-06-06 | 2023-12-14 | Plexium, Inc. | Compounds and pharmaceutical compositions that degrade cdk2 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100571588B1 (ko) * | 1997-12-22 | 2006-04-17 | 바이엘 코포레이션 | 치환 헤테로시클릭 우레아를 이용한 raf 키나제의 억제 |
KR100579792B1 (ko) * | 1998-05-13 | 2006-05-12 | 동화약품공업주식회사 | 신규 2,5-피리딘디카복실산 유도체 |
GB9811427D0 (en) * | 1998-05-29 | 1998-07-22 | Zeneca Ltd | Chemical compounds |
ES2251395T3 (es) * | 1999-07-26 | 2006-05-01 | Banyu Pharmaceutical Co., Ltd. | Derivados de biarilureas. |
ATE305782T1 (de) * | 1999-08-12 | 2005-10-15 | Pharmacia Italia Spa | 3(5)-amino-pyrazolderivate, deren herstellungsverfahren und verwendung als krebshemmende mittel |
US6387900B1 (en) * | 1999-08-12 | 2002-05-14 | Pharmacia & Upjohn S.P.A. | 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents |
OA12097A (en) * | 1999-11-30 | 2006-05-04 | Pfizer Prod Inc | 2,4-Diaminopyrimidine compounds useful as immunosuppressants. |
EP1274706A1 (en) * | 2000-04-18 | 2003-01-15 | Agouron Pharmaceuticals, Inc. | Pyrazoles for inhibiting protein kinases |
-
2001
- 2001-08-24 YU YU14703A patent/YU14703A/sh unknown
- 2001-08-24 CZ CZ2003468A patent/CZ2003468A3/cs unknown
- 2001-08-24 MX MXPA03001785A patent/MXPA03001785A/es not_active Application Discontinuation
- 2001-08-24 EE EEP200300085A patent/EE200300085A/xx unknown
- 2001-08-24 EA EA200300205A patent/EA200300205A1/ru unknown
- 2001-08-24 DZ DZ013398A patent/DZ3398A1/xx active
- 2001-08-24 SK SK200-2003A patent/SK2002003A3/sk not_active Application Discontinuation
- 2001-08-24 IL IL15401601A patent/IL154016A0/xx unknown
- 2001-08-24 OA OA1200300050A patent/OA12368A/en unknown
- 2001-08-24 CN CNA018147615A patent/CN1518543A/zh active Pending
- 2001-08-24 PL PL36074201A patent/PL360742A1/xx not_active Application Discontinuation
- 2001-08-24 NZ NZ523656A patent/NZ523656A/en unknown
- 2001-08-24 EP EP01958287A patent/EP1313710A1/en not_active Withdrawn
- 2001-08-24 AP APAP/P/2001/002266A patent/AP2001002266A0/en unknown
- 2001-08-24 WO PCT/IB2001/001540 patent/WO2002018346A1/en not_active Application Discontinuation
- 2001-08-24 HU HU0302669A patent/HUP0302669A3/hu unknown
- 2001-08-24 AU AU2001280009A patent/AU2001280009A1/en not_active Abandoned
- 2001-08-24 KR KR10-2003-7002894A patent/KR20030027093A/ko not_active Application Discontinuation
- 2001-08-24 JP JP2002523464A patent/JP2004507526A/ja active Pending
- 2001-08-24 CA CA002420363A patent/CA2420363A1/en not_active Abandoned
- 2001-08-24 BR BR0113574-0A patent/BR0113574A/pt not_active IP Right Cessation
- 2001-08-27 UY UY26909A patent/UY26909A1/es not_active Application Discontinuation
- 2001-08-28 HN HN2001000192A patent/HN2001000192A/es unknown
- 2001-08-29 PE PE2001000872A patent/PE20020470A1/es not_active Application Discontinuation
- 2001-08-29 DO DO2001000243A patent/DOP2001000243A/es unknown
- 2001-08-29 AR ARP010104115A patent/AR035345A1/es unknown
- 2001-08-30 TN TNTNSN01132A patent/TNSN01132A1/fr unknown
- 2001-08-30 GT GT200100179A patent/GT200100179A/es unknown
- 2001-08-30 SV SV2001000618A patent/SV2002000618A/es unknown
- 2001-08-31 PA PA20018528101A patent/PA8528101A1/es unknown
-
2003
- 2003-01-13 BG BG107455A patent/BG107455A/xx unknown
- 2003-01-15 CR CR6881A patent/CR6881A/es not_active Application Discontinuation
- 2003-01-16 IS IS6687A patent/IS6687A/is unknown
- 2003-02-07 ZA ZA200301064A patent/ZA200301064B/en unknown
- 2003-02-17 EC EC2003004480A patent/ECSP034480A/es unknown
- 2003-02-21 MA MA27050A patent/MA26946A1/fr unknown
- 2003-02-26 HR HR20030140A patent/HRP20030140A2/hr not_active Application Discontinuation
- 2003-02-28 NO NO20030958A patent/NO20030958L/no not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0113574A (pt) | Derivados de pirazol e uso dos mesmos como inibidores de proteìna quinase | |
BR0112862A (pt) | Derivados de imidazol | |
BR0201691A (pt) | Derivados de tiazol | |
BRPI0416212A (pt) | derivado de piridazinona, composição farmacêutica, uso do derivado, método para o tratamento de um sujeito afligido com uma condição ou doença susceptìvel de melhora pela inibição de fosfodiesterase 4 e produto de combinação | |
NO20064412L (no) | Kondensert heterocykelderivat, medisinsk sammensetning inneholdende det samme og medisinsk anvendelse derav | |
BR0208811A (pt) | Derivados de pirazol para tratamento de hiv | |
BRPI0412526A (pt) | composto, uso de um composto, composição farmacêutica, formulação em aerossol farmacêutica, e, método para o tratamento de um paciente humano ou animal com uma condição anti-inflamatória e/ou alérgica | |
NO20081844L (no) | Terapeutiske forbindelser | |
NO20055496D0 (no) | Pyrazolokinazolinderivater, metoder for deres fremstilling og deres anvendelse som kinaseinhibitorer | |
TR200102782T2 (tr) | Bisiklik heterosikleler, bu bileşikleri ihtiva eden farmasötik kompozisyonlar | |
NO20031024D0 (no) | Bicykliske pyrrolyl amider som glukogen fosforylase inhibitorer | |
BR0015821A (pt) | Derivados de pirimidina | |
ES2182903T3 (es) | Derivados heterociclicos utiles en el tratamiento de enfermedades alergicas o reumaticas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. | |
BR0113291A (pt) | steres de aporfina e seu uso em terapia | |
ES2098947T3 (es) | Derivados de beta,beta-dimetil-4-piperidinoetanamina como inhibidores de la biosintesis del colesterol. | |
BR9807950A (pt) | Composto, composição farmacêutica, uso de um composto, e, processos para tratar ou reduzir o risco de doenças ou condições humanas, o risco de doença inflamatória o risco da dor e para a preparação de um composto | |
DK1124841T3 (da) | Substituerede phenylalkenoylguanidiner, fremgangsmåde til fremstilling deraf, anvendelse deraf som lægemidler eller diagnosemidler og lægemidler, som indeholder dem | |
BR0308786A (pt) | Derivados de ftalimido como inibidores da monoamina oxidase b | |
PT1157015E (pt) | Utilizacao de sistemas 2-amino-triazole policiclicos para a preparacao de medicamentos para tratamento de perturbacoes lipometabolicas, da obesidade e da diabetes tipo ii | |
BR0008519A (pt) | Aplicação de sistemas tiazol policìclicos para apreparação de medicamentos para a profilaxia outratamento da obesidade | |
WO2004037166A3 (en) | Therapeutic guanidines | |
DK1248768T3 (da) | Substituerede acylguanidiner, fremgangsmåde til deres fremstilling, deres anvendelse som medikamenter eller diagnostika samt medikamenter, der indeholder disse | |
DK1218401T3 (da) | 4-Benzylaminoquinolin-konjugat med galdesyre og deres heteroanaloger, fremgangsmåde til deres fremstilling, lægemidler indeholdende disse forbindelser og deres anvendelse | |
ATE440835T1 (de) | Heterozyklische harnstoff-derivate für die behandlung von schmerzen. | |
BR0314709A (pt) | Derivados de pirazol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7O E 8O ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2021 DE 29/09/2009. |